Aripiprazole lauroxil

Aripiprazole lauroxil is a dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. Among its listed roles, it functions as a H1-receptor antagonist, a second generation antipsychotic, a serotonergic agonist and a prodrug. It is a dodecanoate ester, a quinolone, a dichlorobenzene, a N-arylpiperazine, a N-alkylpiperazine, an aromatic ether and a delta-lactam. Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used to treat schizophrenia in adult patients. It is grouped under the following drug class(es): Mood stabilizers and Psychotropic agents. Its therapeutic use is listed as central nervous system (CNS) agents and mood stabilizers. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Aristada and Aristada initio. Its PubChem CID is 49831411.